Treatment Option for Unresectable Hepatocellular Carcinoma

Nov 13 2023

Product Theater 2, Exhibit Hall B - Hynes Convention Center

12:40 - 1:10 PM EST

Description

Supported by: AstraZeneca

This promotional program covers the HIMALAYA trial of the IMFINZI + IMJUDO immunotherapy regimen in patients with unresectable HCC. The presentation has been updated with results from the HIMALAYA 4-year exploratory analysis showing 1 in 4 patients treated with IMFINZI + IMJUDO was alive at 4 years.

Presenter:

Pierre Gholam, MD